ERBB2 and breast cancer: The WSG-ADAPT-HER2 + /HR– trial was a randomized phase 2 study comparing a chemotherapy-free regimen with trastuzumab + pertuzumab (HP) against THP in patients with HER2 + , HR-negative early breast cancer (n = 134) in a neoadjuvant setting [16, 17].